NeOnc Technologies Holdings is a clinical-stage life sciences company engaged on the development and commercialization of central nervous system therapeutics designed to address the persistent challenges of overcoming the blood-brain barrier. Co. is engaged in the research and development of therapies for the treatment of central nervous system disorders. NeOnc has two lead products: NEO100 and NEO212. NEO100 is a purified form of perillyl acid, administered to brain cancer patients via intranasal delivery. Additionally, NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. The NTHI average annual return since 2025 is shown above.
The Average Annual Return on the NTHI average annual return since 2025 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NTHI average annual return since 2025 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NTHI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|